top biopharmaceuticals for glp-1 medication Women with a common hormonal disorder have few good treatment options. Could drugs help? Who are the leading innovators

Summary table of the three obesity drugs with levers for ease of use, efficacy, and pricing

Louis Aronne is a paid consultant and advisory board member for Eli Lilly and Company, the study sponsor and the manufacturer of orforglipron and tirzepatide.

Switching to the oral small molecule glucagon-like peptide-1 (GLP-1) orforglipron after taking injectable GLP-1s helped patients maintain mostbut not allof their weight loss, according to a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators

Recently, BMS terminated the Phase III RELATIVITY-123 trial investigating the combination of Opdivo and the LAG-3 antibody relatlimab in a fixed dose for patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

GLP-1 can act on the central GLP-1 receptors (especially the hypothalamus) and the central satiety center, causing a feeling of satiety and reducing food intake, thus achieving weight loss through appetite suppression